Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

884
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

1.4K
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Association Between Helicobacter Pylori Infection and Liver and Biliary Tract Disorders.

Current health sciences journal·2019
Same author

Helicobacter pylori infection: old and new.

Journal of medicine and life·2017
Same author

The etiopathogenesis of uterine fibromatosis.

Journal of medicine and life·2016
Same author

Psychopathology and psychotherapeutic intervention in diabetes: particularities, challenges, and limits.

Journal of medicine and life·2016
Same author

Diagnostic yield of endoscopic markers for celiac disease.

Journal of medicine and life·2015
Same author

Diagnosis and treatment challenges in a patient with splenic tumor and chronic viral hepatitis.

Journal of medicine and life·2015
Same journal

Healthcare costs of COVID-19 hospitalization in maintenance hemodialysis patients during the first two pandemic waves in Romania: a retrospective cohort study.

Journal of medicine and life·2026
Same journal

Clinical and inflammatory biomarkers predicting emergency surgical management decisions and postoperative outcomes in complicated colon cancer.

Journal of medicine and life·2026
Same journal

Antibiotic stewardship and safety in office-based transrectal prostate biopsy: a single-center retrospective analysis of complications.

Journal of medicine and life·2026
Same journal

Epigenetic mechanisms in preeclampsia: translational therapeutic strategies and precision-medicine perspectives.

Journal of medicine and life·2026
Same journal

Short-term functional outcome and pain assessment after spinal decompression for spondylodiscitis.

Journal of medicine and life·2026
Same journal

Effects of vitamin K administration on liver function, inflammation, and coagulation in chronic viral hepatitis: a retrospective study.

Journal of medicine and life·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Hepatitis C treatment & management.

D Andronescu1, S Diaconu1, N Tiuca1

  • 1"Carol Davila" University of Medicine and Pharmacy, Gastroenterology Department, Emergency University Hospital, Bucharest.

Journal of Medicine and Life
|March 22, 2014
PubMed
Summary
This summary is machine-generated.

Pegylated interferon alfa (PEG-IFN alfa) and ribavirin combination therapy is standard for hepatitis C virus (HCV). Adding protease inhibitors significantly improves treatment outcomes for genotype 1 HCV infections.

Keywords:
hepatitis Cinterferonsprotease inhibitorsribavirin

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Experiment Videos

Last Updated: May 2, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Pegylated interferon alfa (PEG-IFN alfa) and ribavirin is the standard treatment for hepatitis C virus (HCV).
  • HCV genotype 1 shows a less favorable response to therapy compared to genotypes 2 and 3.
  • Treatment duration varies by genotype, with 12 months for genotype 1 and 6 months for genotypes 2 and 3.

Purpose of the Study:

  • To review current treatment guidelines for hepatitis C virus (HCV) infection.
  • To evaluate the efficacy of combination therapy including PEG-IFN alfa and ribavirin.
  • To assess the impact of protease inhibitors on HCV treatment outcomes.

Main Methods:

  • Review of current clinical guidelines and treatment protocols for HCV.
  • Analysis of treatment response rates based on HCV viral genotype.
  • Evaluation of combination therapy efficacy in different patient populations, including those with HIV coinfection.

Main Results:

  • Standard therapy duration is 6 months for genotypes 2 and 3, and 12 months for genotype 1.
  • For patients with HIV coinfection, an additional 6 months of therapy is recommended if there is a response.
  • Acute HCV infection should be treated for 6 months.
  • Protease inhibitors added to PEG-IFN alfa and ribavirin significantly improve sustained virologic response rates, especially for genotype 1 HCV.

Conclusions:

  • Treatment duration for HCV should be guided by viral genotype and presence of viremia.
  • Protease inhibitors represent a significant advancement in HCV treatment, particularly for genotype 1.
  • Combination therapy with PEG-IFN alfa, ribavirin, and protease inhibitors is emerging as the new standard of care.